Ginkgo Bioworks Holdings Inc (NYSE: DNA) is a synthetic biology company that operates a cell programming platform enabling customers to design and engineer biological products. The company makes money through cell engineering services fees, biosecurity services, and downstream value sharing arrangements tied to customer product milestones and royalties. The filing excerpts provided do not contain sufficient detail to characterize Ginkgo's competitive position, segment revenue breakdown, customer concentration, geographic mix, leadership tenure, or specific FY2025 financial metrics with the specificity required for attribution. Based solely on the available filing excerpt, which consists primarily of SEC cover-page boilerplate, no additional specific operational or financial claims can be made. Further detail on revenue, customers, and market position would require access to the substantive body of the 10-K filed on 2026-02-26 (accession 0001628280-26-012346).

Source: SEC 10-K, filed 2026-02-26

Industry: Biological Products, (No Diagnostic Substances) Peers: Ashland Inc Axalta Coating Systems Ltd Balchem Corp Celanese Corp Eastman Chemical Co Element Solutions Inc Livent Corp. International Flavors & Fragrances Inc RPM International Inc Sherwin-Williams Co